Bli medlem
Bli medlem

Du är här


BioStock Investor Meeting: Cyxone presents

Carl-Magnus Högerkorp recently assumed the role as acting CEO of Cyxone.  The biopharmaceutical company is currently awaiting approval of the phase II study with the candidate Rabeximod in rheumatoid arthritis. At the BioStock Investor Meeting in Stockholm, Högerkorp talked about the preparations for the start of the study and what lies ahead for the company.

See the presentation at

This is a press release from BioStock - Connecting Innovation & Capital.

Författare Cision